TMDX
TransMedics Group, Inc. NASDAQ Listed May 2, 2019$72.78
Mkt Cap $2.5B
52w Low $70.00
3.2% of range
52w High $156.00
50d MA $114.50
200d MA $122.29
P/E (TTM)
17.9x
EV/EBITDA
27.7x
P/B
7.2x
Debt/Equity
1.0x
ROE
40.2%
P/FCF
31.0x
RSI (14)
—
ATR (14)
—
Beta
2.08
50d MA
$114.50
200d MA
$122.29
Avg Volume
915.1K
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
200 Minuteman Road · Andover, MA 01810 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.62 | 0.30 | -51.6% | 94.93 | -21.1% | -23.2% | -23.2% | — | — | — | — |
| Feb 24, 2026 | AMC | 0.41 | 0.57 | +39.0% | 137.78 | +1.6% | -4.3% | -2.3% | +5.4% | +6.7% | +7.4% | — |
| Oct 29, 2025 | AMC | 0.37 | 0.66 | +78.4% | 134.32 | -5.1% | +1.1% | -2.1% | -7.1% | -9.0% | -7.3% | — |
| Jul 30, 2025 | AMC | 0.48 | 0.92 | +91.7% | 107.70 | +14.8% | +10.5% | +11.9% | +19.3% | +16.8% | +10.3% | — |
| May 8, 2025 | AMC | 0.29 | 0.70 | +141.4% | 93.20 | +23.0% | +19.6% | +27.4% | +31.0% | +31.3% | +30.7% | — |
| Feb 27, 2025 | AMC | 0.22 | 0.19 | -13.6% | 72.12 | +2.1% | +5.8% | -3.9% | -4.2% | -6.5% | -9.5% | — |
| Oct 28, 2024 | AMC | 0.29 | 0.12 | -58.6% | 126.24 | -27.8% | -29.9% | -35.1% | -35.1% | -34.7% | -32.7% | — |
| Jul 31, 2024 | AMC | 0.21 | 0.35 | +66.7% | 142.26 | +15.9% | +6.5% | +5.5% | +4.4% | +9.7% | +2.5% | — |
| Apr 30, 2024 | AMC | 0.03 | 0.35 | +974.8% | 94.13 | +16.9% | +24.9% | +32.2% | +36.0% | +40.9% | +35.2% | — |
| Feb 26, 2024 | AMC | 0.02 | 0.12 | +500.0% | 77.74 | +16.4% | +14.1% | +5.5% | +5.0% | +6.4% | +11.9% | — |
| Nov 6, 2023 | AMC | -0.18 | -0.12 | +33.3% | 40.19 | +41.8% | +51.2% | +52.3% | +45.0% | +42.7% | +48.4% | — |
| Aug 3, 2023 | AMC | -0.15 | -0.03 | +80.0% | 87.53 | -12.6% | -8.3% | -21.7% | -24.2% | -26.1% | -26.3% | — |
| May 1, 2023 | AMC | -0.25 | -0.08 | +68.0% | 77.85 | +0.9% | -5.2% | -6.2% | -5.7% | -4.9% | -8.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6 | Oppenheimer | Downgrade | Outperform → Perform | — | $94.93 | $74.91 | -21.1% | -23.2% | -23.2% | — | — | — |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $100.70 | $101.08 | +0.4% | +4.1% | +6.6% | +8.6% | +8.4% | +13.2% |
| Mar 9 | Stifel | Maintains | Hold → Hold | — | $129.61 | $125.26 | -3.4% | +4.0% | +1.0% | -0.5% | -6.4% | -4.7% |
| Feb 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $137.78 | $140.00 | +1.6% | -4.3% | -2.3% | +5.4% | +6.7% | +7.4% |
| Feb 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $137.78 | $140.00 | +1.6% | -4.3% | -2.3% | +5.4% | +6.7% | +7.4% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $137.78 | $140.00 | +1.6% | -4.3% | -2.3% | +5.4% | +6.7% | +7.4% |
| Feb 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $137.78 | $140.00 | +1.6% | -4.3% | -2.3% | +5.4% | +6.7% | +7.4% |
| Feb 25 | JP Morgan | Maintains | Neutral → Neutral | — | $137.78 | $140.00 | +1.6% | -4.3% | -2.3% | +5.4% | +6.7% | +7.4% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $125.04 | $126.99 | +1.6% | -2.5% | -3.2% | +2.1% | +3.4% | +2.5% |
| Dec 8 | Needham | Maintains | Buy → Buy | — | $136.51 | $137.26 | +0.5% | +0.1% | -1.3% | -3.9% | -6.5% | -7.1% |
| Dec 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $150.42 | $154.06 | +2.4% | -5.8% | -6.9% | -7.8% | -9.2% | -9.2% |
| Oct 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $134.32 | $127.50 | -5.1% | +1.1% | -2.1% | -7.1% | -9.0% | -7.3% |
| Oct 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $134.32 | $127.50 | -5.1% | +1.1% | -2.1% | -7.1% | -9.0% | -7.3% |
| Oct 23 | Needham | Upgrade | Hold → Buy | — | $119.54 | $123.74 | +3.5% | +7.8% | +9.2% | +10.8% | +8.5% | +12.4% |
| Oct 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $111.71 | $108.58 | -2.8% | -0.4% | +0.8% | +3.6% | +5.3% | +7.3% |
| Aug 25 | Needham | Maintains | Hold → Hold | — | $119.85 | $120.50 | +0.5% | -4.1% | -3.9% | -2.1% | -2.6% | -4.1% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $118.97 | $117.91 | -0.9% | +1.3% | +8.0% | +5.7% | -0.1% | -2.5% |
| Jul 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $116.88 | $118.44 | +1.3% | -1.0% | -3.0% | -3.7% | -6.0% | -11.4% |
| Jun 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $141.96 | $140.15 | -1.3% | -4.1% | -12.7% | -13.0% | -10.2% | -6.6% |
| Jun 17 | Needham | Maintains | Hold → Hold | — | $141.96 | $140.15 | -1.3% | -4.1% | -12.7% | -13.0% | -10.2% | -6.6% |
| Jun 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $128.74 | $128.85 | +0.1% | +0.8% | +5.3% | +8.0% | +8.3% | +9.4% |
| Jun 3 | Needham | Maintains | Hold → Hold | — | $123.94 | $125.16 | +1.0% | +3.9% | +4.7% | +9.4% | +12.2% | +12.5% |
| May 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $93.20 | $114.60 | +23.0% | +19.6% | +27.4% | +31.0% | +31.3% | +30.7% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $93.20 | $114.60 | +23.0% | +19.6% | +27.4% | +31.0% | +31.3% | +30.7% |
| Apr 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $90.19 | $91.14 | +1.1% | +2.5% | +2.0% | +0.3% | -0.2% | +2.2% |
| Apr 23 | Needham | Maintains | Hold → Hold | — | $91.21 | $95.00 | +4.2% | +1.1% | +3.3% | +2.5% | -1.1% | +1.3% |
| Mar 26 | Needham | Maintains | Hold → Hold | — | $70.79 | $71.79 | +1.4% | -0.7% | -0.5% | -3.1% | -5.0% | -3.6% |
| Mar 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $66.03 | $65.73 | -0.5% | +2.5% | +1.6% | -2.5% | +3.8% | +2.5% |
| Feb 5 | Needham | Maintains | Hold → Hold | — | $72.14 | $72.86 | +1.0% | +3.4% | +1.9% | +0.6% | -2.6% | -5.6% |
| Dec 17 | JP Morgan | Downgrade | Overweight → Neutral | — | $64.22 | $61.32 | -4.5% | +2.3% | -5.2% | -5.7% | -3.9% | -2.4% |
| Dec 11 | Baird | Maintains | Outperform → Outperform | — | $68.99 | $68.80 | -0.3% | -2.4% | -4.8% | -6.9% | -6.9% | -4.8% |
| Dec 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $68.99 | $68.80 | -0.3% | -2.4% | -4.8% | -6.9% | -6.9% | -4.8% |
| Dec 11 | Needham | Maintains | Hold → Hold | — | $68.99 | $68.80 | -0.3% | -2.4% | -4.8% | -6.9% | -6.9% | -4.8% |
| Dec 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $85.14 | $77.08 | -9.5% | -16.1% | -15.2% | -22.2% | -19.8% | -18.0% |
| Dec 3 | Needham | Maintains | Hold → Hold | — | $85.14 | $77.08 | -9.5% | -16.1% | -15.2% | -22.2% | -19.8% | -18.0% |
| Nov 22 | Needham | Downgrade | Buy → Hold | — | $79.34 | $76.00 | -4.2% | -4.2% | -1.0% | +1.6% | +9.8% | +9.3% |
| Nov 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $82.92 | $80.89 | -2.4% | -6.9% | -4.3% | -8.3% | -5.2% | -2.8% |
| Nov 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $82.92 | $80.89 | -2.4% | -6.9% | -4.3% | -8.3% | -5.2% | -2.8% |
| Nov 18 | TD Cowen | Maintains | Buy → Buy | — | $80.48 | $78.21 | -2.8% | +0.6% | +3.0% | -4.1% | -1.4% | -5.5% |
| Oct 29 | Baird | Maintains | Outperform → Outperform | — | $126.24 | $91.15 | -27.8% | -29.9% | -35.1% | -35.1% | -34.7% | -32.7% |
| Oct 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $126.24 | $91.15 | -27.8% | -29.9% | -35.1% | -35.1% | -34.7% | -32.7% |
| Oct 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $126.24 | $91.15 | -27.8% | -29.9% | -35.1% | -35.1% | -34.7% | -32.7% |
| Oct 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $126.24 | $91.15 | -27.8% | -29.9% | -35.1% | -35.1% | -34.7% | -32.7% |
| Oct 29 | JP Morgan | Maintains | Overweight → Overweight | — | $126.24 | $91.15 | -27.8% | -29.9% | -35.1% | -35.1% | -34.7% | -32.7% |
| Oct 29 | Needham | Maintains | Buy → Buy | — | $126.24 | $91.15 | -27.8% | -29.9% | -35.1% | -35.1% | -34.7% | -32.7% |
| Oct 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $138.97 | $137.98 | -0.7% | -3.5% | -0.6% | -1.3% | -2.2% | -2.7% |
| Aug 23 | Needham | Maintains | Buy → Buy | — | $173.34 | $173.63 | +0.2% | +1.3% | -1.8% | +1.6% | -2.5% | -3.9% |
| Aug 2 | Stephens & Co. | Maintains | Overweight → Overweight | — | $151.51 | $147.40 | -2.7% | -0.9% | -2.0% | +3.0% | -3.7% | +6.8% |
| Aug 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $142.26 | $164.84 | +15.9% | +6.5% | +5.5% | +4.4% | +9.7% | +2.5% |
| Aug 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $142.26 | $164.84 | +15.9% | +6.5% | +5.5% | +4.4% | +9.7% | +2.5% |
No insider trades available.
8-K
TransMedics Group, Inc. -- 8-K Filing
TransMedics released a valuation allowance on deferred tax assets, improving fourth-quarter financial results through a non-cash accounting adjustment that benefits shareholders' equity without affecting operational performance.
Feb 27
8-K
TransMedics Group, Inc. -- 8-K Filing
TransMedics reported full-year 2025 financial results for its organ transplant technology platform, with the company continuing to advance its life-saving medical devices.
Feb 24
8-K
TransMedics Group, Inc. -- 8-K Filing
TransMedics extended consultant Ranganath's non-executive employment through September 2026, maintaining his base salary and 2025 bonus eligibility, indicating management stability continuity.
Feb 4
Data updated apr 27, 2026 5:03am
· Source: massive.com